Panmure Gordon reissued their buy rating on shares of Hutchison China MediTech Limited (LON:HCM) in a research note issued to investors on Tuesday. Panmure Gordon currently has a GBX 3,840 ($49.66) price objective on the stock.

Separately, Beaufort Securities reaffirmed a buy rating on shares of Hutchison China MediTech Limited in a research report on Tuesday, August 1st.

Hutchison China MediTech Limited (LON:HCM) opened at 3840.00 on Tuesday. Hutchison China MediTech Limited has a 1-year low of GBX 1,760.00 and a 1-year high of GBX 3,520.00. The company has a 50-day moving average of GBX 13,448.40 and a 200-day moving average of GBX 5,696.26. The firm’s market capitalization is GBX 2.33 billion.

COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at

In other news, insider Karen Jean Ferrante purchased 10,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average cost of GBX 3,475 ($44.94) per share, with a total value of £347,500 ($449,430.94).

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.